These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8533725)
1. 1994 biotechnology drug approvals. Manuel SM Am Pharm; 1995 Mar; NS35(3):12-3. PubMed ID: 8533725 [No Abstract] [Full Text] [Related]
2. Competing for the treasure in exceptions. Cox TM Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870 [No Abstract] [Full Text] [Related]
3. [Gaucher's disease: a second drug is now available]. Stirnemann J Rev Prat; 2003 Sep; 53(13):1401-2. PubMed ID: 14558259 [No Abstract] [Full Text] [Related]
4. In brief: Taliglucerase (Elelyso) for Gaucher disease. Med Lett Drugs Ther; 2012 Jul; 54(1394):56. PubMed ID: 22966489 [No Abstract] [Full Text] [Related]
5. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable. Berger J; Stirnemann J; Bourgne C; Pereira B; Pigeon P; Heraoui D; Froissart R; Rapatel C; Rose C; Belmatoug N; Berger MG Br J Haematol; 2012 Apr; 157(2):274-7. PubMed ID: 22224474 [No Abstract] [Full Text] [Related]
6. Taliglucerase alfa approved for Gaucher disease. Traynor K Am J Health Syst Pharm; 2012 Jun; 69(12):1009. PubMed ID: 22644968 [No Abstract] [Full Text] [Related]
7. In brief: Velaglucerase (Vpriv) for Gaucher's disease. Med Lett Drugs Ther; 2010 May; 52(1337):36. PubMed ID: 20431522 [No Abstract] [Full Text] [Related]
8. Cerezyme--recombinant protein treatment for Gaucher's disease. Hoppe H J Biotechnol; 2000 Jan; 76(2-3):259-61. PubMed ID: 10656341 [No Abstract] [Full Text] [Related]
9. Drug development. Orphan drug windfalls? Gershon D Nature; 1992 Jan; 355(6359):381. PubMed ID: 1734267 [No Abstract] [Full Text] [Related]
10. Why Genzyme can charge so much for Cerezyme. Anand G Wall St J (East Ed); 2005 Nov; ():A15. PubMed ID: 16502533 [No Abstract] [Full Text] [Related]
11. PEG-asparaginase. Fu CH; Sakamoto KM Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798 [TBL] [Abstract][Full Text] [Related]
12. Treatment regimens in Gaucher's disease. Beutler E Lancet; 1995 Aug; 346(8974):581-2. PubMed ID: 7658807 [No Abstract] [Full Text] [Related]
13. Using the International Gaucher Disease Registry data: can we devise a virtuous circle for treated patients? Elstein D; Zimran A Am J Hematol; 2008 Dec; 83(12):887-9. PubMed ID: 18980272 [No Abstract] [Full Text] [Related]
15. Velaglucerase (Vpriv) for Gaucher's disease. Med Lett Drugs Ther; 2010 May; 52(1337):36. PubMed ID: 20508578 [No Abstract] [Full Text] [Related]
16. Enzyme replacement therapy in a child with Gaucher disease. Masood Y; Ali AS J Coll Physicians Surg Pak; 2006 Dec; 16(12):786-8. PubMed ID: 17125641 [TBL] [Abstract][Full Text] [Related]
17. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy. Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116 [No Abstract] [Full Text] [Related]